From advances in graft versus host disease treatment to updates on H5N1 and Duchenne muscular dystrophy research, the DDN editors break down the news this week.
After tragedy struck during a 1960s clinical trial, development of a vaccine for RSV ground to a halt. But as new RSV vaccine candidates enter late-stage clinical trials, a safe and effective vaccine is finally in sight.